MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
39.73
-0.53
-1.32%
After Hours: 39.73 0 0.00% 16:04 10/13 EDT
OPEN
40.26
PREV CLOSE
40.26
HIGH
40.35
LOW
39.67
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
55.67
52 WEEK LOW
27.00
MARKET CAP
6.67B
P/E (TTM)
103.22
1D
5D
1M
3M
1Y
5Y
1D
Alkermes to present new data on alixorexton, LUMRYZ
TipRanks · 9h ago
Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026
Benzinga · 9h ago
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Barchart · 14h ago
Weekly Report: what happened at ALKS last week (1005-1009)?
Weekly Report · 1d ago
Alkermes (ALKS) Dropped, So What Is Driving Attention Now?
Simply Wall St · 4d ago
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
TipRanks · 4d ago
Alkermes (ALKS) Receives a Buy from RBC Capital
TipRanks · 4d ago
Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study
TipRanks · 6d ago
More
About ALKS
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.